Popular antidepressant associated with a dramatic increase in suicidal thoughts amongst men

Oct 14, 2009

Nortriptyline has been found to cause a ten-fold increase in suicidal thoughts in men when compared to its competitor escitalopram. These findings are published in the open access journal BMC Medicine.

The research was carried out by Dr. Nader Perroud from the Institute of Psychiatry, Kings College London, who headed up GENDEP, an international team. Dr Perroud said "Suicidal thoughts and behaviours during antidepressant treatment have prompted warnings by regulatory bodies". He continued "the aim of our study was to investigate the emergence and worsening of suicidal thoughts during treatment with two different types of antidepressant."

Both escitalopram and nortriptyline have their effect through the mood modulating systems. The former is a selective (SSRI), preventing serotonin from re-entering the cell and thereby prolonging its effect on nerve synapses. The latter is a tricyclic antidepressant that inhibits the reuptake of noradrenaline, and to a lesser extent, that of serotonin.

The study was carried out on 811 individuals with moderate to severe unipolar depression. Whilst an overall trend in reduction of suicidal thoughts was observed, men who took nortriptyline were found to have a 9.8-fold increase in emerging suicidal thoughts and a 2.4-fold increase in worsening suicidal thoughts compared to those who took escitalopram.

Perroud concludes, "Our findings that treatment-emerging and worsening suicidal thoughts may also be associated with psychomotor activation triggered by antidepressants needs to be investigated in future studies. The study also refutes the idea that newer antidepressants such as the SSRIs are worse than older medications in terms of increasing ."

More information: Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based for Depression (GENDEP): a clinical trial, Nader Perroud, et at., BMC Medicine (in press), http://www.biomedcentral.com/bmcmed/

Source: BioMed Central (news : web)

Explore further: Mirabegron for overactive bladder: Added benefit not proven

add to favorites email to friend print save as pdf

Related Stories

Ketamine reduces suicidality in depressed patients

Sep 10, 2009

Drug treatment options for depression can take weeks for the beneficial effects to emerge, which is clearly inadequate for those at immediate risk of suicide. However, intravenous (IV) ketamine, a drug previously used as ...

Suicide risk factors consistent across nations

Feb 01, 2008

Risk factors for suicidal thoughts, plans and attempts are consistent across countries, and include having a mental disorder and being female, younger, less educated, and unmarried. So says new research from a Harvard University ...

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

8 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

RJ32
1 / 5 (1) Oct 15, 2009
Want to get rid of depression? Change to an attitude of gratitude. It is impossible to be grateful and depressed at the same time and the choice is yours.
jonnyboy
Oct 15, 2009
This comment has been removed by a moderator.